| abstract |
Provided are compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods for their synthesis, and methods for their therapeutic and / or prophylactic uses. Such compounds alone or in combination with incretin peptides such as GLP-1 (7-36) and GLP-1 (9-36), or peptide-based therapeutic agents such as exenatide and liraglutide, GLP- It can act as a modulator or potentiator of one receptor and has the following general structure (where “(I)” represents either or both of the R and S forms of the compound): Where A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein As defined in. |